Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

Song Yee Kim, Jungho Kim, Deok Ryun Kim, youngae kang, Sungyoung Bong, Jonghee Lee, Suyeon Kim, Nam Suk Lee, Bora Sim, Sangnae Cho, Young Sam Kim, Hyejon Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB. Methods: IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data. Results: The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but did not increase significantly after 2 months of treatment in patients with active TB. Conclusions: Unstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in patients with active pulmonary TB.

Original languageEnglish
Article number240
JournalBMC Infectious Diseases
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 May 29

Fingerprint

Pulmonary Tuberculosis
Biomarkers
Urine
Proteins
Virus Diseases
Therapeutics
Chemokine CXCL10
Chronic Hepatitis C
Nonparametric Statistics
Serum
Hepacivirus
Lung Diseases
Interferon-gamma
Blood Proteins
Tuberculosis
Vaccines
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Lung
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

Kim, Song Yee ; Kim, Jungho ; Kim, Deok Ryun ; kang, youngae ; Bong, Sungyoung ; Lee, Jonghee ; Kim, Suyeon ; Lee, Nam Suk ; Sim, Bora ; Cho, Sangnae ; Kim, Young Sam ; Lee, Hyejon. / Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis. In: BMC Infectious Diseases. 2018 ; Vol. 18, No. 1.
@article{d8bba81767274a77b824559924a6c5c5,
title = "Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis",
abstract = "Background: Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB. Methods: IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data. Results: The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but did not increase significantly after 2 months of treatment in patients with active TB. Conclusions: Unstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in patients with active pulmonary TB.",
author = "Kim, {Song Yee} and Jungho Kim and Kim, {Deok Ryun} and youngae kang and Sungyoung Bong and Jonghee Lee and Suyeon Kim and Lee, {Nam Suk} and Bora Sim and Sangnae Cho and Kim, {Young Sam} and Hyejon Lee",
year = "2018",
month = "5",
day = "29",
doi = "10.1186/s12879-018-3144-3",
language = "English",
volume = "18",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis. / Kim, Song Yee; Kim, Jungho; Kim, Deok Ryun; kang, youngae; Bong, Sungyoung; Lee, Jonghee; Kim, Suyeon; Lee, Nam Suk; Sim, Bora; Cho, Sangnae; Kim, Young Sam; Lee, Hyejon.

In: BMC Infectious Diseases, Vol. 18, No. 1, 240, 29.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

AU - Kim, Song Yee

AU - Kim, Jungho

AU - Kim, Deok Ryun

AU - kang, youngae

AU - Bong, Sungyoung

AU - Lee, Jonghee

AU - Kim, Suyeon

AU - Lee, Nam Suk

AU - Sim, Bora

AU - Cho, Sangnae

AU - Kim, Young Sam

AU - Lee, Hyejon

PY - 2018/5/29

Y1 - 2018/5/29

N2 - Background: Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB. Methods: IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data. Results: The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but did not increase significantly after 2 months of treatment in patients with active TB. Conclusions: Unstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in patients with active pulmonary TB.

AB - Background: Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB. Methods: IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data. Results: The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but did not increase significantly after 2 months of treatment in patients with active TB. Conclusions: Unstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in patients with active pulmonary TB.

UR - http://www.scopus.com/inward/record.url?scp=85047668271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047668271&partnerID=8YFLogxK

U2 - 10.1186/s12879-018-3144-3

DO - 10.1186/s12879-018-3144-3

M3 - Article

VL - 18

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 240

ER -